Lenka Sadilkova
Director, Non-Clinical Projects Operations Eli Lilly & Co.
Dr. Lenka Kyrych Sadilkova is a senior drug discovery and translational pharmacology leader with 20+ years in preclinical drug development, including 15+ years focused on antibody–drug conjugates (ADCs). Her expertise spans bioconjugation, antibody engineering, and PK/PD-driven translational pharmacology, including humanized mouse models. PhD in biochemistry, molecular biology, and gerontology; multiple peer-reviewed publications.
She is Director of R&D Projects at Eli Lilly, following its acquisition of Mablink Bioscience, where she served as Director of Nonclinical Projects and Head of Preclinical R&D, leading a lead ADC program through regulatory submission into clinical trials. Previously, over a decade at SOTIO Biotech (Scientist to Director of Pharmacology) advanced multiple ADC programs into clinical evaluation.
Seminars
- Which datasets provide the greatest confidence when progressing a candidate?
- How can teams determine whether a preclinical signal is meaningful enough to justify investment?
- What are the biggest barriers to translating promising biology into clinical success?
- Audience Q&A
- Which preclinical endpoints, biomarkers, and model characteristics are most consistently associated with successful clinical outcomes?
- How can organisations use clinical observations, imaging, and translational data to improve confidence in model-derived decisions and reduce late-stage risk?
- What are the most common reasons promising preclinical programmes fail in patients, and how can model strategies be refined to improve predictability?
- Audience Q&As
